Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-PCS02 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-PCS02 | ACTIVE_COMPARATOR | - |
| Sterile Normal Saline (0.9% NaCl) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-PCS02 | DRUG | Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion |
| Sterile Normal Saline (0.9% NaCl) | DRUG | Calculated volume to match active comparator |
Inclusion Criteria: * Elevated LDL-C of \>3.0 mmol/L and \<5.7 mmol/L * Fasting triglyceride concentration ≤2.8 mmol/L * Body weight \>60.0 kg; body mass index (BMI) between 19.00 kg/m2 and \<35.00 kg/m2 * Adequate blood counts, liver and renal function * May not received any lipid lowering drug/ag...
ALN-PCS02 is an investigational drug being studied for the treatment of elevated LDL-Cholesterol (LDL-C). It is being developed as a potential therapy for patients with high levels of LDL cholesterol, a condition associated with increased cardiovascular risk.
ALN-PCS02 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALNY. The company is conducting clinical research to evaluate the safety and tolerability of this investigational drug.
ALN-PCS02 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under clinical investigation for its potential use in treating elevated LDL cholesterol.
ALN-PCS02 has one completed clinical trial, registered as NCT01437059. This Phase 1 study evaluated the safety and tolerability of ALN-PCS02 in subjects with elevated LDL-Cholesterol. The trial was conducted in the United Kingdom and enrolled 32 participants.
ALN-PCS02 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being studied under this name in clinical trials for elevated LDL-Cholesterol.